Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KurtVedder who wrote (1011)	2/1/1998 9:23:00 PM
From: Richard Dooling	Read Replies (1) \| Respond to of 1359

>>It, as well as all other newsletters, should not be judged on the stock performance of the companies they cover but rather on the wealth of information they provide. Plus, in the long run (which is the only way in which biotech's should be invested), I am confident that Neuroinvestment will outperform most, if not all, other newsletters in the field.<< DearKurt: For those of us who have received the NeuroInvestment newsletter from the beginning, we are well-satisfied with both the wealth of information and the stock performance of the selected companies. Because of NI I was able to buy Neurex at 2 (still holding at what 17?) and Guilford at half what it is now? I also doubled my money twice playing Cortex back when it was jumping up and down. No expert could have predicted the Redux debacle. I sold for tax losses and am back in again. Even if I did not invest in biotech companies, I would subscribe to NI for the information on neuroscience and neurochemistry. The writing is excellent and the topics fascinating, and how much more fun to make money while following along. Richard Dooling dooling.com